Spinal cord stimulation (SCS) Neurological

Information for healthcare professionals
on therapies and products

EXPLORE PRODUCTS
Review Outcomes
Learn About DTM™ SCS
View Info
Explore Resources

DTM™ SCS therapy
Spinal cord stimulation

DTM™ SCS is a proprietary, multiplexed algorithm coordinating multiple signals at multiple anatomical targets. In a randomized control trial (RCT) at 12 months, DTM™ SCS provided superior, sustained pain relief compared to conventional stimulation.1

Learn more about DTM™ SCS

DTM™ SCS endurance therapy

DTM™ SCS endurance therapy is an energy modified, differential target multiplexed therapy offering more longevity on Vanta™ recharge-free INS and rapid recharge on Intellis™ rechargeable INS. Three-month results show meaningful pain relief, satisfaction and quality of life improvements.2

View 3-month results

Learn about Vanta™ SCS
Your advantage over pain

Vanta™ SCS gives you an advantage over pain. This high-performance, recharge-free device offers more longevity, DTM™ SCS endurance therapy, and unmatched MRI access.

Explore Vanta™ SCS
Front view of the Medtronic Intellis device with AdaptiveStim technology, used for spinal cord stimulation therapy

Discover the
Intellis™ SCS platform

The Intellis™ SCS is the world’s smallest implantable neurostimulator. This high-performance rechargeable device offers unrivaled battery chemistry with >95% battery capacity at 9 years, personalized programming and unmatched MRI access.

LEARN ABOUT INTELLIS™ SCS
Front view of Medtronic Intellis AdaptiveStim device

Reimbursement coding

Download
resources.

View Tools

MRI resources

Find MRI information
and resources.

Find Resources

Continuing  education

Access e-learning content on RTG academy.

Visit RTG Academy
1

Fishman M, Cordner H, Justiz R, et al. 12-Month results from multicenter, open-label, randomized controlled clinical trial comparing differential target multiplexed spinal cord stimulation and traditional spinal cord stimulation in subjects with chronic intractable back pain and leg pain. Pain Pract. 2021. doi: 10.1111/papr.13066.

2

Peacock, Provenzano, Fishman, et al. A prospective multi-center study of a differential target multiplexed™ stimulation derivative in therapy-naive patients: Primary endpoint and 3-month outcomes. Poster presented at: North american neuromodulation society (NANS) annual meeting. Jan. 13-15, 2022.